Q4 2024 Earnings Call Transcript February 12, 2025 Ascendis Pharma A/S beats earnings expectations. Reported EPS is $-0.68699 ...

CEO Jan Mikkelsen highlighted 2024 as a pivotal year, with SKYTROFA achieving €200 million in revenue and a 6.5% share of the U.S. growth hormone market. The product now holds 45% of the U.S.

Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...

U.S.-listed shares of Ascendis Pharma climbed more than 7% in Thursday’s premarket session, setting the stage for their best open since early January. Late on Wednesday, the company reported ...

Reports Q4 revenue EUR 173.92M vs. EUR 137.7M last year. “Having achieved pivotal milestones in 2024, Ascendis is positioned to continue strong ...

Its growth hormone therapy, SKYTROFA (lonapegsomatropin-tcgd, developed as TransCon hGH) is approved in the US and in sundry locations around the world. Its FDA approval came in 08/2021 as a once ...

fo - Results for all three TransCon hGH starting dose cohorts, in first clinical trial of an indication outside of growth hormone deficiency, showed a safety and tolerability profile comparable to ...

At the heart of the agreement is an exclusive worldwide license to Copenhagen-based Ascendis' TransCon technology ... a long-acting growth hormone for children with growth hormone deficiency.

AIMS To evaluate the effects of discontinuing growth hormone (GH) treatment on energy expenditure and body composition, which might help predict those most likely to benefit from early reintroduction ...

Growth stocks are made up of companies that are set to grow their earnings and revenue by an abundant amount compared to the rest of the market, which also has an impact on the price of each ...

You will be able to get a quick price and instant permission to reuse the content in many different ways. Growth hormone (GH) has been in clinical use for four decades and there has been much ...